A decrease in MCP2/CCL8 levels may affect the development and progression of local intestinal inflammation and tissue destruction in patients with CD through cellular and molecular interactions between epithelial, immune, and inflammatory cells. The gene discussed is CCL8; the disease is inflammatory response.